Characterization of rifampicin-resistant Mycobacterium tuberculosis in Taiwan

被引:33
作者
Hwang, HY [1 ]
Chang, CY [1 ]
Chang, LL [1 ]
Chang, SF [1 ]
Chang, YH [1 ]
Chen, YJ [1 ]
机构
[1] Kaohsiung Med Univ, Sch Med, Dept Microbiol, Kaohsiung 807, Taiwan
关键词
D O I
10.1099/jmm.0.05045-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Sixty-three rifampicin-resistant (Rif(r)) isolates of Mycobacterium tuberculosis from Kaohsiung, Taiwan, were analysed for mutations in the core region (69 bp, codons 511-533) of the rpoB gene. Some 84.1 % (53/63) of the resistant isolates showed mutations in this region, especially in codons 531 (41.5 %), 526 (18.9 %), 516 (15.1 %) and 533 (7.5 %). Five novel alleles of a total of 16 different types of mutations were identified in Rif(r) isolates. Ten Rif(r) isolates (15.9 %) exhibited no mutations in the core region of rpoB. Also, they did not show mutations in another 365 bp fragment (codons 99-220) of rpoB. The agar proportion method was used to determine the relationship between the degree of rifampicin resistance and alterations in the core region of rpoB. The results revealed that the mean MIC was 92.38 mug ml(-1) for the 53 isolates with a mutation in the core region, whereas the mean MIC of the other 10 isolates without mutations was only 24.8 mug ml(-1). This indicates that the isolates with mutations in the core region had higher levels of resistance than those without mutations in this region. IS6110 restriction fragment length polymorphism (RFLP) was used for typing of 55 Rif(r) M. tuberculosis isolates. Isolates contained two to 19 copies of IS6110, with sizes ranging from 600 to 16 000 bp. The majority (85 %) contained six to 16 copies. No strains lacking IS61 10 were found. A total of 54 of 55 RFLP types were defined at the 90 % similarity level. The observation of varied IS6110-associated banding patterns indicates that an outbreak of drug-resistant tuberculosis did not occur in this area.
引用
收藏
页码:239 / 245
页数:7
相关论文
共 36 条
[1]   Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay [J].
Bártfai, Z ;
Somoskövi, A ;
Ködmön, C ;
Szabó, N ;
Puskás, E ;
Kosztolányi, L ;
Faragó, E ;
Mester, J ;
Parsons, LM ;
Salfinger, M .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (10) :3736-3739
[2]   IS6110 - CONSERVATION OF SEQUENCE IN THE MYCOBACTERIUM-TUBERCULOSIS COMPLEX AND ITS UTILIZATION IN DNA FINGERPRINTING [J].
CAVE, MD ;
EISENACH, KD ;
MCDERMOTT, PF ;
BATES, JH ;
CRAWFORD, JT .
MOLECULAR AND CELLULAR PROBES, 1991, 5 (01) :73-80
[3]  
Chiang IH, 1998, J FORMOS MED ASSOC, V97, P581
[4]   LABORATORY CONTAMINATION OF MYCOBACTERIUM-TUBERCULOSIS CULTURES [J].
DUNLAP, NE ;
HARRIS, RH ;
BENJAMIN, WH ;
HARDEN, JW ;
HAFNER, D .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (05) :1702-1704
[5]   Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country [J].
Dye, C ;
Scheele, S ;
Dolin, P ;
Pathania, V ;
Raviglione, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07) :677-686
[6]   AN OUTBREAK OF MULTIDRUG-RESISTANT TUBERCULOSIS AMONG HOSPITALIZED-PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
EDLIN, BR ;
TOKARS, JI ;
GRIECO, MH ;
CRAWFORD, JT ;
WILLIAMS, J ;
SORDILLO, EM ;
ONG, KR ;
KILBURN, JO ;
DOOLEY, SW ;
CASTRO, KG ;
JARVIS, WR ;
HOLMBERG, SD .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (23) :1514-1521
[7]   TREATMENT OF 171 PATIENTS WITH PULMONARY TUBERCULOSIS RESISTANT TO ISONIAZID AND RIFAMPIN [J].
GOBLE, M ;
ISEMAN, MD ;
MADSEN, LA ;
WAITE, D ;
ACKERSON, L ;
HORSBURGH, CR .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08) :527-532
[8]   Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates [J].
Heep, M ;
Brandstätter, B ;
Rieger, U ;
Lehn, N ;
Richter, E ;
Rüsch-Gerdes, S ;
Niemann, S .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (01) :107-110
[9]   Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis [J].
Heep, M ;
Rieger, U ;
Beck, D ;
Lehn, N .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1075-1077
[10]   PERMEABILITY BARRIER TO RIFAMPIN IN MYCOBACTERIA [J].
HUI, J ;
GORDON, N ;
KAJIOKA, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1977, 11 (05) :773-779